14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
A series of registration deadlines are fast approaching for a new law in Illinois that will have a s...
Read More >
UPDATED February 3, 2020. As we stated in our January 27th Alert, employers must continue monitoring...
Read More >
Effective January 1, 2020, it will be unlawful for Nevada employers to reject job applicants on the ...
Read More >
The NRC will soon issue in the Federal Register a proposed rulemaking to amend the drug testing requ...
Read More >
Recently, we have addressed the evolving regulatory landscape for per- and poly-fluoroalkyl substanc...
Read More >
Connecticut has joined the growing number of states passing or enhancing laws aimed to deter sexual ...
Read More >